An overview of the
current data from PsoProtectMe
Current Data
We are committed to sharing data and are delighted to provide open access to summary information from PsoProtectMe. These data are preliminary so should not be used to inform clinical decision making.
Click here to read our research paper detailing PsoProtect data. A summary can be found on the Psoriasis Association website here.
Our research paper detailing shielding behaviour can be found here. A summary can also be found on the Psoriasis Association website here.
See our full list of research publications here.
Summary data from PsoProtectMe’s first 4501 participants.
Participants per country (≥10 participants):
| Country | Participants | Country | Participants |
|---|---|---|---|
| Argentina | 217 | Netherlands | 35 |
| Australia | 38 | Norway | 21 |
| Brazil | 139 | Panama | 11 |
| Canada | 58 | Paraguay | 10 |
| Chile | 363 | Peru | 19 |
| Denmark | 51 | Philippines | 57 |
| Dominican Republic | 10 | Poland | 94 |
| France | 11 | Portugal | 204 |
| Greece | 13 | Singapore | 14 |
| Hong Kong | 18 | South Africa | 16 |
| India | 48 | Spain | 77 |
| Ireland | 60 | Sweden | 40 |
| Italy | 40 | United Kingdom | 2253 |
| Japan | 107 | United States | 317 |
| Malaysia | 10 | Other (<10) | 142 |
| Mexico | 10 |
Average age: 45 years (range 3-91)
Average BMI: 26.8 kg/m2
Type of psoriasis: 3721 plaque psoriasis, 950 guttate psoriasis, 251 pustular psoriasis, 93 erythrodema
Gender:
Smoking status:
Coexisting psoriatic arthritis:
Type of psoriasis treatment:
Psoriasis severity change during the pandemic:
Have you been diagnosed with or thought you had COVID-19?
Did you go to hospital A&E due to your COVID-19?
Did you stay in hospital due to your COVID-19?
Has your COVID-19 infection got better?